MCID: CRV047
MIFTS: 51

Cervical Cancer, Somatic malady

Genetic diseases (common), Cancer diseases, Reproductive diseases categories

Aliases & Classifications for Cervical Cancer, Somatic

About this section

Aliases & Descriptions for Cervical Cancer, Somatic:

Name: Cervical Cancer, Somatic 46 9
Cervical Cancer 46 30 8 10 44 32 2
Carcinoma of Cervix 8 22
Cervix Carcinoma 8 61
Carcinoma of the Cervix Uteri 8
Neoplasm of Uterine Cervix 8
Malignant Tumor of Cervix 61
Uterine Cervical Neoplasm 61
 
Tumor of the Cervix Uteri 8
Carcinoma Cervix Uteri 8
Cervix Uteri Cancer 8
Cervical Carcinoma 44
Cervical Neoplasm 8
Cancer of Cervix 8
Cervix Cancer 8


Classifications:



Summaries for Cervical Cancer, Somatic

About this section
MedlinePlus:32 The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. cervical cancer is caused by a virus called hpv. the virus spreads through sexual contact. most women's bodies are able to fight hpv infection. but sometimes the virus leads to cancer. you're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have hiv infection. cervical cancer may not cause any symptoms at first. later, you may have pelvic pain or bleeding from the vagina. it usually takes several years for normal cells in the cervix to turn into cancer cells. your health care provider can find abnormal cells by doing a pap test to examine cells from the cervix. you may also have an hpv test. if your results are abnormal, you may need a biopsy or other tests. by getting regular screenings, you can find and treat any problems before they turn into cancer. treatment may include surgery, radiation therapy, chemotherapy, or a combination. the choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. vaccines can protect against several types of hpv, including some that can cause cancer. nih: national cancer institute

MalaCards based summary: Cervical Cancer, Somatic, also known as cervical cancer, is related to papilloma and retinoblastoma, and has symptoms including neoplasmand abnormality of the cervical spine. An important gene associated with Cervical Cancer, Somatic is FGFR3 (fibroblast growth factor receptor 3), and among its related pathways are Akt Signaling and TGF-Beta Pathway. The compounds melphalan and bortezomib have been mentioned in the context of this disorder. Affiliated tissues include the cervix, skeletal muscle and breast, and related mouse phenotypes are craniofacial and limbs/digits/tail.

Disease Ontology:8 A female reproductive organ cancer that is located in the cervix.

CDC:2 Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

Description from OMIM:46 603956

Related Diseases for Cervical Cancer, Somatic

About this section

Diseases related to Cervical Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 173)
idRelated DiseaseScoreTop Affiliating Genes
1papilloma30.9FGFR3, TP53
2retinoblastoma30.3TP53, FGFR3
3leukemia30.1FGFR3, TP53
4burkitt lymphoma29.8FGFR3, TP53
5melanoma29.6FGFR3, TP53
6prostate cancer29.5FGFR3, TP53
7cervicitis11.6
8cervical intraepithelial neoplasia10.8
9endotheliitis10.6
10hypoxia10.6
11poorly differentiated endocrine carcinoma of the cervix uteri10.6
12glassy cell carcinoma of the cervix uteri10.6
13adenoid basal carcinoma of the cervix uteri10.6
14papillary carcinoma of the cervix uteri10.6
15malignant müllerian mixed tumor of the cervix uteri10.6
16malignant peripheral neuroectodermal tumor of the cervix uteri10.6
17malignant germ cell tumor of the cervix uteri10.6
18adenoiditis10.5
19cervical adenoid cystic carcinoma10.5
20neuroectodermal tumor10.5
21vaginitis10.5
22adenocarcinoma10.4
23cervix small cell carcinoma10.3
24cervical clear cell adenocarcinoma10.3
25cystic basal cell carcinoma10.3
26cervical endometrioid adenocarcinoma10.3
27verrucous carcinoma10.3
28basal cell carcinoma10.3
29cervical adenosquamous carcinoma10.3
30in situ carcinoma10.3
31cervix uteri carcinoma in situ10.3
32lymphedema10.2
33adenosquamous carcinoma10.2
34breast cancer10.2
35myoma10.2
36herpes simplex10.2
37sarcoma10.2
38nasopharyngitis10.1
39arthritis10.1
40small cell neuroendocrine carcinoma10.1
41lymphangitis10.1
42keratinizing squamous cell carcinoma10.1
43septic arthritis10.1
44fibrous histiocytoma10.1
45anal squamous cell carcinoma10.1
46histiocytoma10.1
47cystic fibrosis10.1
48insulin-like growth factor i10.1
49trichomoniasis10.1
50hydronephrosis10.1

Graphical network of the top 20 diseases related to Cervical Cancer, Somatic:



Diseases related to cervical cancer, somatic

Symptoms for Cervical Cancer, Somatic

About this section


Clinical features from OMIM:

603956

HPO human phenotypes related to Cervical Cancer, Somatic:

id Description Frequency HPO Source Accession
1 neoplasm HP:0002664
2 abnormality of the cervical spine HP:0003319

Drugs & Therapeutics for Cervical Cancer, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Avastin13 38 BEVACIZUMAB Genentech Approved July 2009
FDA Label: Avastin
Malady that Drug Treats: renal cell carcinoma & Colorectal Cancer
Indications and Usage:13 Avastin is a vascular endothelial growth factor-specific angiogenesis; inhibitor indicated for the treatment of:; Metastatic colorectal cancer, with intravenous 5-fluorouracil-based; chemotherapy for first- or second-line treatment. (1.1); Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- or; fluoropyrimidine-oxaliplatin-based chemotherapy for second-line; treatment in patients who have progressed on a first-line Avastincontaining; regimen. (1.1); Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel; for first line treatment of unresectable, locally advanced, recurrent or; metastatic disease. (1.2); Glioblastoma, as a single agent for adult patients with progressive disease; following prior therapy. (1.3); -Effectiveness based on improvement in objective response rate. No data; available demonstrating improvement in disease-related symptoms or; survival with Avastin.; Metastatic renal cell carcinoma with interferon alfa (1.4); Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel; and topotecan in persistent, recurrent, or metastatic disease. (1.5); Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary; peritoneal cancer, in combination with paclitaxel, pegylated liposomal; doxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of colon; cancer. (1.1)
DrugBank Targets:11 1. Vascular endothelial growth factor A; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10. Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR); 697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial; 698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration; 699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction; 700 of microvascular growth and inhibition of metastatic disease progression
2
Cervarix13 38 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline Approved October 2009
FDA Label: -
Malady that Drug Treats: prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18
Indications and Usage:13 -
DrugBank Targets: -
Mechanism of Action:13 
Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins
Action: activates/ provokes production
FDA: -
3
Gardasil13 38 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006
FDA Label: Gardasil
Malady that Drug Treats: Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:13 GARDASIL is a vaccine indicated in girls and women 9 through 26; years of age for the prevention of the following diseases caused by; Human Papillomavirus (HPV) types included in the vaccine:; Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16; and 18 (1.1); Genital warts (condyloma acuminata) caused by HPV types 6 and; 11 (1.1); And the following precancerous or dysplastic lesions caused by HPV; types 6, 11, 16, and 18:; Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervical; adenocarcinoma in situ (AIS) (1.1); Cervical intraepithelial neoplasia (CIN) grade 1 (1.1); Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1); Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1); Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1); GARDASIL is indicated in boys and men 9 through 26 years of age for; the prevention of the following diseases caused by HPV types included; in the vaccine:; Anal cancer caused by HPV types 16 and 18 (1.2); Genital warts (condyloma acuminata) caused by HPV types 6 and; 11 (1.2); And the following precancerous or dysplastic lesions caused by HPV; types 6, 11, 16, and 18:; Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2); Limitations of GARDASIL Use and Effectiveness:; GARDASIL does not eliminate the necessity for women to; continue to undergo recommended cervical cancer screening.; (1.3, 17); Recipients of GARDASIL should not discontinue anal cancer; screening if it has been recommended by a health care provider.; (1.3, 17); GARDASIL has not been demonstrated to provide protection; against disease from vaccine and non-vaccine HPV types to which; a person has previously been exposed through sexual activity.; (1.3, 14.4, 14.5); GARDASIL is not intended to be used for treatment of active; external genital lesions; cervical, vulvar, vaginal, and anal; cancers; CIN; VIN; VaIN, or AIN. (1.3); GARDASIL has not been demonstrated to protect against; diseases due to HPV types not contained in the vaccine. (1.3,; 14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, and; GARDASIL protects only against those vulvar, vaginal, and anal; cancers caused by HPV 16 and 18. (1.3); GARDASIL does not protect against genital diseases not caused; by HPV. (1.3); Vaccination with GARDASIL may not result in protection in all; vaccine recipients. (1.3); GARDASIL has not been demonstrated to prevent HPV-related; CIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets: -
Mechanism of Action:13 
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest that; the efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Human; beings develop a humoral immune response to the vaccine, although the exact mechanism of protection; is unknown.

Drug clinical trials:

Search ClinicalTrials for Cervical Cancer, Somatic

Search NIH Clinical Center for Cervical Cancer, Somatic

Genetic Tests for Cervical Cancer, Somatic

About this section

Genetic tests related to Cervical Cancer, Somatic:

id Genetic test Affiliating Genes
1 Carcinoma of Cervix22

Anatomical Context for Cervical Cancer, Somatic

About this section

MalaCards organs/tissues related to Cervical Cancer, Somatic:

31
Skeletal muscle, Breast, Cervix, Uterus, Testes, Smooth muscle, Myeloid, Lung, B cells, Endothelial

FMA organs/tissues related to Cervical Cancer, Somatic:

14
The cervix

Animal Models for Cervical Cancer, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Cervical Cancer, Somatic:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053829.1FGFR3, TP53
2MP:00053719.0FGFR3, TP53
3MP:00020068.8FGFR3, TP53

Publications for Cervical Cancer, Somatic

About this section

Variations for Cervical Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer, Somatic:

63
id Symbol AA change Variation ID SNP ID
1FGFR3p.Ser249CysVAR_004149

Clinvar genetic disease variations for Cervical Cancer, Somatic:

5
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_000546.5(TP53): c.747G> T (p.Arg249Ser)single nucleotide variantPathogenicrs28934571GRCh37Chr 17, 7577534: 7577534
2FGFR3NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys)single nucleotide variantPathogenicrs121913483GRCh37Chr 4, 1803568: 1803568

Expression for genes affiliated with Cervical Cancer, Somatic

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Cervical Cancer, Somatic patients vs. healthy controls: 30 (show all 51)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1MYH3myosin, heavy chain 3, skeletal muscle, embryonicSkeletal Muscle+4.270.000
2SERPINA6serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6Breast-3.720.029
3GPM6Bglycoprotein M6BBreast-3.710.023
4ARHGAP36Rho GTPase activating protein 36Breast-3.700.028
5MUC15mucin 15, cell surface associatedBreast-3.660.015
6PDE1Cphosphodiesterase 1C, calmodulin-dependent 70kDaBreast-3.660.041
7TSPAN5tetraspanin 5Breast-3.640.023
8LOC388692uncharacterized LOC388692Breast-3.620.000
9BEND7BEN domain containing 7Breast-3.620.003
10MARVELD3MARVEL domain containing 3Breast-3.610.013
11TUBB2Btubulin, beta 2B class IIbBreast-3.570.034
12MEX3Cmex-3 RNA binding family member CBreast-3.560.020
13METmet proto-oncogeneBreast-3.550.019
14ERICH3glutamate-rich 3Breast-3.550.001
15HSD17B2hydroxysteroid (17-beta) dehydrogenase 2Breast-3.550.036
16C2orf40chromosome 2 open reading frame 40Breast-3.550.039
17PAMR1peptidase domain containing associated with muscle regeneration 1Breast-3.540.002
18COBLcordon-bleu WH2 repeat proteinBreast-3.530.013
19KRT15keratin 15Breast-3.520.049
20CDH1cadherin 1, type 1, E-cadherin (epithelial)Breast-3.520.017
21LOC389906zinc finger protein 839 pseudogeneBreast-3.520.002
22SYNMsynemin, intermediate filament proteinBreast-3.520.001
23CA2carbonic anhydrase IIBreast-3.460.047
24NTF4neurotrophin 4Breast-3.450.016
25ADAM28ADAM metallopeptidase domain 28Breast-3.430.022
26EIF1eukaryotic translation initiation factor 1Breast-3.420.009
27CDC14Acell division cycle 14ABreast-3.410.005
28SLC27A6solute carrier family 27 (fatty acid transporter), member 6Breast-3.370.026
29CTHcystathionase (cystathionine gamma-lyase)Breast-3.360.013
30EPB41L5erythrocyte membrane protein band 4.1 like 5Breast-3.360.032
31LOC728705uncharacterized LOC728705Breast-3.330.026
32SERPINA1serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1Breast-3.270.017
33CCL28chemokine (C-C motif) ligand 28Breast-3.270.018
34AMDHD1amidohydrolase domain containing 1Breast-3.260.013
35GSTA1glutathione S-transferase alpha 1Breast-3.240.011
36FAM201Afamily with sequence similarity 201, member ABreast-3.230.032
37GOPCgolgi-associated PDZ and coiled-coil motif containingBreast-3.220.041
38TRIM29tripartite motif containing 29Breast-3.210.012
39GLRA3glycine receptor, alpha 3Breast-3.210.048
40PM20D2peptidase M20 domain containing 2Breast-3.190.032
41PTNpleiotrophinBreast-3.140.019
42PDE4Dphosphodiesterase 4D, cAMP-specificBreast-3.140.011
43ANGPTL7angiopoietin-like 7Breast-3.140.003
44C1orf168chromosome 1 open reading frame 168Breast-3.130.011
45OXTRoxytocin receptorBreast-3.120.016
46CHST9carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9Breast-3.120.021
47PIGYphosphatidylinositol glycan anchor biosynthesis, class YBreast-3.110.011
48DMDdystrophinBreast-3.100.050
49BBOX1butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1Breast-3.090.025
50RAI14retinoic acid induced 14Breast-3.070.022
51CYP2J2cytochrome P450, family 2, subfamily J, polypeptide 2Breast-3.030.034

Search GEO for disease gene expression data for Cervical Cancer, Somatic.

Pathways for genes affiliated with Cervical Cancer, Somatic

About this section

Pathways related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 15)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.1FGFR3, TP53
2
Show member pathways
9.1FGFR3, TP53
3
Show member pathways
9.1TP53, FGFR3
4
Show member pathways
9.1FGFR3, TP53
5
Show member pathways
9.1FGFR3, TP53
6
Show member pathways
9.1FGFR3, TP53
7
Show member pathways
9.1FGFR3, TP53
89.1TP53, FGFR3
9
Show member pathways
Signaling Pathways in Glioblastoma36
9.1FGFR3, TP53
10
Show member pathways
9.1FGFR3, TP53
11
Show member pathways
MAPK signaling pathway36
9.1TP53, FGFR3
129.1FGFR3, TP53
13
Show member pathways
9.1FGFR3, TP53
149.1FGFR3, TP53
159.1FGFR3, TP53

Compounds for genes affiliated with Cervical Cancer, Somatic

About this section
Sources:
44Novoseek, 50PharmGKB, 11DrugBank, 24HMDB
See all sources

Compounds related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

idCompoundScoreTop Affiliating Genes
1melphalan44 50 1111.3FGFR3, TP53
2bortezomib44 50 1111.3FGFR3, TP53
3guanine44 24 1111.2FGFR3, TP53
4doxorubicin44 50 1111.2FGFR3, TP53
5paraffin449.1TP53, FGFR3
6arginine449.1FGFR3, TP53
7oligonucleotide449.0FGFR3, TP53
8vegf448.8FGFR3, TP53

GO Terms for genes affiliated with Cervical Cancer, Somatic

About this section

Cellular components related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1endoplasmic reticulumGO:00057839.1FGFR3, TP53

Biological processes related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1negative regulation of transcription from RNA polymerase II promoterGO:00001229.1FGFR3, TP53
2positive regulation of neuron apoptotic processGO:00435258.8FGFR3, TP53

Sources for Cervical Cancer, Somatic

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet